- Home
- UCL vs STRO Comparison
UCL vs STRO Comparison
Compare UCL & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- STRO
- Stock Information
- Founded
- UCL 2014
- STRO 2003
- Country
- UCL Hong Kong
- STRO United States
- Employees
- UCL N/A
- STRO N/A
- Industry
- UCL Telecommunications Equipment
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UCL Consumer Discretionary
- STRO Health Care
- Exchange
- UCL Nasdaq
- STRO Nasdaq
- Market Cap
- UCL 70.6M
- STRO 77.7M
- IPO Year
- UCL 2020
- STRO 2018
- Fundamental
- Price
- UCL $1.83
- STRO $0.76
- Analyst Decision
- UCL
- STRO Hold
- Analyst Count
- UCL 0
- STRO 7
- Target Price
- UCL N/A
- STRO $3.97
- AVG Volume (30 Days)
- UCL 58.4K
- STRO 1.4M
- Earning Date
- UCL 08-13-2025
- STRO 08-12-2025
- Dividend Yield
- UCL N/A
- STRO N/A
- EPS Growth
- UCL N/A
- STRO N/A
- EPS
- UCL 0.09
- STRO N/A
- Revenue
- UCL $92,256,000.00
- STRO $66,434,000.00
- Revenue This Year
- UCL $6.09
- STRO N/A
- Revenue Next Year
- UCL $7.01
- STRO N/A
- P/E Ratio
- UCL $19.62
- STRO N/A
- Revenue Growth
- UCL 7.65
- STRO N/A
- 52 Week Low
- UCL $0.80
- STRO $0.52
- 52 Week High
- UCL $3.30
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- UCL 54.00
- STRO 44.92
- Support Level
- UCL $1.79
- STRO $0.67
- Resistance Level
- UCL $1.99
- STRO $0.79
- Average True Range (ATR)
- UCL 0.16
- STRO 0.07
- MACD
- UCL -0.03
- STRO -0.01
- Stochastic Oscillator
- UCL 19.05
- STRO 34.52
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.